Project Grant R21DA059630
Award Date
9/30/24
Completion Date
8/31/26
Dollars Obligated
$189K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Little Rock, AR 72205, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,916,991.00 to support a Phase 1B clinical trial of the novel therapeutic agent MT-110 for the reduction of methamphetamine use disorder (MUD). The trial will recruit up to 44 patients to test 5 dose levels of MT-110 and determine central nervous system drug concentrations. The primary endpoints are focused on assessing the safety and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $189,896 to develop and pilot test the "Patient Reported Outcome Measures to Individualize Treatment and Improve Retention" (RETAIN) program intervention package. The goal is to capture patient-reported outcome measures (PROMs) in Federally Qualified Health Center (FQHC)-based opioid use disorder (OUD) treatment, with the objective of...
This $810,668 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate an immunotherapeutic compound called DRHQ as a potential treatment for stimulant use disorder, specifically methamphetamine addiction. The primary objective is to assess DRHQ's effects on drug-seeking behavior, cognitive function, and inflammation in preclinical animal models of stimulant use disorder. The research...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) provides $318,257 to Cari Health, Inc. to develop a therapeutic monitoring system (TMS) for remote medication compliance tracking of methadone treatment for opioid use disorder (OUD). The key products and services to be delivered include: 1) Integrating an electrochemical sensor, microneedle array, and data pipeline into a prototype wearable...
The National Institute on Drug Abuse (NIDA) awarded a $223,715 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Washington to explore the neurobehavioral effects of concurrent opioid and methamphetamine use disorders. The key objectives are to: 1) Define the behavioral profile of dual opioid-methamphetamine use disorders in a rodent model, comparing polysubstance and mono-substance addiction patterns, and 2) Map neural activation patterns within...
This federal Project Grant award of $1,481,760 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the "Methamphetamine Activation of Inflammasome and Altered Immunity in HIV (MAIA) Study" at Emory University. The primary objective is to investigate how methamphetamine use leads to inflammasome activation and immune dysfunction in people living with HIV on antiretroviral therapy, even when viral loads are...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $634,048 to The University of Kentucky Research Foundation to conduct a human laboratory study on advancing troriluzole as a treatment for methamphetamine use disorder (MUD). The overarching goal is to translate preclinical findings on troriluzole's effects on reducing methamphetamine intake and seeking behaviors into clinical evidence. The...
This Project Grant award of $983,672.00, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to provide unparalleled insight into the nature and extent of HIV and methamphetamine use in the brain, as well as the host-immune factors that facilitate inflammation and brain injury. The key products and services to be delivered under this award include the development and implementation of innovative single-cell...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), provides $441,000 to the University Enterprises Corporation at CSUSB to investigate the impact of adolescent nicotine exposure on methamphetamine self-administration in female rats. The research aims to determine if adolescent nicotine exposure increases methamphetamine intake, reinstatement, or relapse in both male and...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is for the development of a novel liquid methadone dispensing device and smart container system called the MOUD-EID. The total funding amount is $319,000 and the project period is from August 1, 2024 to July 31, 2025. The key products/services to be delivered include: (A) an inner container with electromechanical valves to precisely dispense up to...